Key Highlights
- Revenue grew 46.0% to USD 8.04 million.
- Net income was USD 953 thousand, a USD 1.1 million increase.
- Earnings per share were USD 0.10.
- Gross Margin was 44.2%, which is 130 basis points higher.
ImmuCell (NASDAQ:ICCC) reported third quarter 2026 Revenue of USD 8.04 million, a 46.0% increase compared with the third quarter of 2025, aided in part by the absence of distributor restocking headwinds that had adversely affected sales in the prior-year quarter. Net Income was USD 953 thousand, a USD 1.1 million increase, and Earnings Per Share were USD 0.10.
Gross margin was 44.2%, which is 130 basis points higher than in the third quarter of 2025, reflecting higher pricing and Manufacturing execution, partially offset by the shift of certain product development expenses to costs of goods sold.
Financial Detail
Gross profit was USD 3.56 million, compared with USD 2.36 million. Sales, Marketing and administrative expenses were USD 2.42 million, compared with USD 1.65 million, and product development expenses were USD 177 thousand, compared with USD 694 thousand.
For the nine months ended September 30, 2026, Gross Profit was USD 10.65 million, compared with USD 8.54 million. Sales, marketing and administrative expenses for the nine months were USD 7.17 million, compared with USD 4.55 million, and product development expenses were USD 614 thousand, compared with USD 2.28 million.
Balance Sheet
Cash and cash equivalents were USD 7.91 million, compared with USD 3.81 million at the prior Balance Sheet date. Inventory was USD 9.86 million, compared with USD 9.27 million, and net Working Capital was USD 16.90 million, compared with USD 12.97 million.
Total Assets were USD 47.96 million, compared with USD 42.53 million, and stockholders' Equity was USD 32.77 million, compared with USD 27.06 million.
Management Commentary
President and chief executive officer Olivier te Boekhorst said the quarter's revenue, gross margin and net income, compared with a net loss of about USD 140 thousand in the third quarter of 2025, indicate that the company's focus on its First Defense product is working. He noted that the company stopped investing in a new product for subclinical mastitis called Re-Tain, which was also driven by its contract manufacturer's inability to obtain good manufacturing practice approval from the U.S. Food and Drug Administration.
He said the company is investing in capacity expansion and colostrum sourcing capabilities for future demand, and referred to a plan to invest USD 8 million to increase manufacturing capacity by the end of 2027, with those efforts projected to be completed on time and within budget.
The company said it has negotiated a new, larger USD 3 million line of Credit with its bank, which it anticipates signing during the fourth quarter of 2026, and that, given its cash position, it has terminated its at-the-market offering.
Management said domestic sales for the quarter grew 29.2% to USD 6.9 million, while international sales grew 573% to USD 1.1 million, with sales to Canada accounting for the majority of international growth, boosted in large part by the clearing of 2025 back orders. It said the company decided in December 2025 to focus exclusively on First Defense, its bovine scours preventative product line, and that it estimates First Defense captures about 34% of spending on bovine scours biological products in the United States. Management also referred to a new freeze dryer planned for installation in the first half of 2027, which it anticipates roughly tripling its freeze-drying capacity.
ImmuCell Q3 2026 Earnings: Key Takeaways
ImmuCell reported third quarter 2026 revenue of USD 8.04 million, net income of USD 953 thousand and earnings per share of USD 0.10. Cash and cash equivalents were USD 7.91 million, and the company terminated its at-the-market offering.






Please wait processing your request...